Mads Ravnborg

Summary

Affiliation: Copenhagen University Hospital
Country: Denmark

Publications

  1. ncbi Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis
    Bodil Petersen
    Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Mult Scler 12:247-52. 2006
  2. ncbi [Magnetic resonance imaging in the diagnosis and follow-up of multiple sclerosis]
    Henrik Kahr Mathiesen
    Rigshospitalet, Dansk Multipel Sclerose Center, København Ø
    Ugeskr Laeger 170:2579-81. 2008
  3. ncbi [Proton magnetic resonance spectroscopy in the evaluation of cognitive disturbances]
    Henrik Kahr Mathiesen
    H S Hvidovre Hospital, MR afdelingen, Hvidovre
    Ugeskr Laeger 168:357-9. 2006
  4. ncbi [Diagnosis of multiple sclerosis: revision of the McDonald criteria]
    Henrik Kahr Mathiesen
    Rigshospitalet, Dansk Multipel Sclerose Center
    Ugeskr Laeger 169:3853-6. 2007
  5. ncbi Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis
    Henrik Kahr Mathiesen
    Danish Research Centre for Magnetic Resonance, Copenhagen University Hospital Hvidovre, Kettegaard Alle 30, DK 2650 Hvidovre, Denmark
    Arch Neurol 63:533-6. 2006
  6. ncbi Antibodies to IFN-beta: the Danish National IFN-beta Project
    Per Soelberg Sorensen
    Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Neurology 61:S27-8. 2003
  7. ncbi The relationship between MRI and PET changes and cognitive disturbances in MS
    Per Soelberg Sørensen
    Department of Neurology 2082, Danish MS Research Center, Copenhagen University Hospital, Rigshospitalet, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    J Neurol Sci 245:99-102. 2006
  8. ncbi Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey
    Per Soelbeg Sorensen
    Danish Multiple Sclerosis Research Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Mult Scler 12:253-64. 2006
  9. doi Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial
    Mads Ravnborg
    Danish Multiple Sclerosis Research Center, University of Copenhagen and Department of Neurology, Rigshospitalet, Copenhagen, Denmark
    Lancet Neurol 9:672-80. 2010
  10. ncbi Cognitive impairment in newly diagnosed multiple sclerosis patients: a 4-year follow-up study
    Agnete Jønsson
    Department of Neurology, Section 6131, Danish Multiple Sclerosis Centre, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    J Neurol Sci 245:77-85. 2006

Collaborators

Detail Information

Publications17

  1. ncbi Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis
    Bodil Petersen
    Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Mult Scler 12:247-52. 2006
    ..The main objective was to follow serum levels of neutralizing antibodies (NABs) against interferon-beta (IFNbeta) after discontinuation of IFNbeta therapy...
  2. ncbi [Magnetic resonance imaging in the diagnosis and follow-up of multiple sclerosis]
    Henrik Kahr Mathiesen
    Rigshospitalet, Dansk Multipel Sclerose Center, København Ø
    Ugeskr Laeger 170:2579-81. 2008
    ..The use of MRI in MS diagnosis and follow-up is reviewed. The acquirements to the MRI protocol given by the revised McDonald diagnostic criteria are discussed...
  3. ncbi [Proton magnetic resonance spectroscopy in the evaluation of cognitive disturbances]
    Henrik Kahr Mathiesen
    H S Hvidovre Hospital, MR afdelingen, Hvidovre
    Ugeskr Laeger 168:357-9. 2006
    ..Magnetic resonance spectroscopy seems to be a way to monitor the efficacy of existing and new treatments to prevent the development of cognitive deficits in a number of diseases...
  4. ncbi [Diagnosis of multiple sclerosis: revision of the McDonald criteria]
    Henrik Kahr Mathiesen
    Rigshospitalet, Dansk Multipel Sclerose Center
    Ugeskr Laeger 169:3853-6. 2007
    ..A standard clinical approach to the diagnosis of multiple sclerosis, including the use of a standard MRI protocol, VEP, CSF evaluation and other paraclinical tests is suggested...
  5. ncbi Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis
    Henrik Kahr Mathiesen
    Danish Research Centre for Magnetic Resonance, Copenhagen University Hospital Hvidovre, Kettegaard Alle 30, DK 2650 Hvidovre, Denmark
    Arch Neurol 63:533-6. 2006
    ..Whole-brain N-acetyl aspartate (NAA), a measure of neuronal function, can be assessed by multislice echo-planar spectroscopic imaging...
  6. ncbi Antibodies to IFN-beta: the Danish National IFN-beta Project
    Per Soelberg Sorensen
    Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Neurology 61:S27-8. 2003
  7. ncbi The relationship between MRI and PET changes and cognitive disturbances in MS
    Per Soelberg Sørensen
    Department of Neurology 2082, Danish MS Research Center, Copenhagen University Hospital, Rigshospitalet, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    J Neurol Sci 245:99-102. 2006
    ..Measurements of global NAA using multi-slice EPSI is a new promising method for measurement of the global neuron capacity and can be repeated with only little discomfort and without any risk for the patient...
  8. ncbi Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey
    Per Soelbeg Sorensen
    Danish Multiple Sclerosis Research Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Mult Scler 12:253-64. 2006
    ..The aim of the present study was to provide data on the use of immunomodulatory therapies in a population comprising all treated patients with relapsing-remitting multiple sclerosis (RRMS) in Denmark...
  9. doi Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial
    Mads Ravnborg
    Danish Multiple Sclerosis Research Center, University of Copenhagen and Department of Neurology, Rigshospitalet, Copenhagen, Denmark
    Lancet Neurol 9:672-80. 2010
    ..We therefore aimed to investigate the combination of cyclic methylprednisolone and interferon beta for the treatment of relapsing-remitting multiple sclerosis...
  10. ncbi Cognitive impairment in newly diagnosed multiple sclerosis patients: a 4-year follow-up study
    Agnete Jønsson
    Department of Neurology, Section 6131, Danish Multiple Sclerosis Centre, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    J Neurol Sci 245:77-85. 2006
    ..Methodological problems are discussed, especially the practice effect and the importance of identifying sensitive and stable test measures...
  11. ncbi A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis
    N Koch-Henriksen
    Danish Multiple Sclerosis Registry, Rigshospitalet, Copenhagen, Denmark
    Neurology 66:1056-60. 2006
    ..To investigate whether the efficacy of interferon-beta (IFNbeta) treatment of relapsing-remitting MS (RR-MS) was influenced by type, dose, and frequency of administration...
  12. ncbi [Natalizumab (Tysabri)]
    Mads Ravnborg
    Rigshospitalet, Neurocentret, Dansk Multipel Sklerose Center, København Ø
    Ugeskr Laeger 169:3184-7. 2007
    ..The clinical use of the treatment will be restricted initially due to uncertainty about the risk of opportunistic infections in long term treatment...
  13. ncbi Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
    Per Soelberg Sorensen
    Department of Neurology, Institute for Inflammation Research, Rigshospitalet, Copenhagen, Denmark
    Lancet 362:1184-91. 2003
    ..We aimed to assess the clinical effect of neutralising antibodies...
  14. ncbi Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
    Ludwig Kappos
    University Hospital, Basel, Switzerland
    Lancet Neurol 6:431-41. 2007
    ..Maintaining clinical vigilance allows for early suspension of natalizumab in potential cases of PML, thereby increasing the opportunity for immune reconstitution, which may improve prognosis if PML is confirmed...
  15. ncbi [Is "quality of life" a relevant goal in clinical studies of rehabilitation?]
    Mads Ravnborg
    Neurologisk Ambulatorium, Roskilde Sygehus, DK 4000 Roskilde
    Ugeskr Laeger 170:859-61. 2008
    ..Further efforts are required in order to engineer instruments that are in accordance with the WHO-ICF concept, which will make studies of the interaction between "symptoms", "activity", "social participation" and QoL meaningful...
  16. ncbi [Multidisciplinary rehabilitation of patients with multiple sclerosis. A survey of a Cochrane review]
    Mads Ravnborg
    Roskilde Sygehus, Neurologisk Klinik, DK 4000 Roskilde
    Ugeskr Laeger 170:1138-41. 2008
  17. ncbi [Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis]
    Soelberg Sørensen
    Sclerose Forskningsenheden, Københavns MS Center, Neurologisk Afdeling 2082, H S Rigshospitalet
    Ugeskr Laeger 166:3606-9. 2004